SCHEMBL7168287

SCHEMBL7168287

CCOc1ccc(S(=O)(=O)N2CCN(CCO)CC2)cc1-c1nc2c(OC)cccc2c(=O)[nH]1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 20/20 0.67
PDE3B Q13370 2/20 0.67
PDE3A Q14432 2/20 0.67
PDE1A P54750 8/20 0.64
PDE1B Q01064 8/20 0.64
PDE1C Q14123 8/20 0.64
HDAC1 Q13547 1/20 0.55
HDAC6 Q9UBN7 1/20 0.55
PDE2A O00408 1/20 0.54
ABCC4 O15439 1/20 0.54
ABCC5 O15440 1/20 0.54
PDE6D O43924 1/20 0.54
PDE8A O60658 1/20 0.54
PDE9A O76083 1/20 0.54
ABCB11 O95342 1/20 0.54
CYP3A4 P08684 1/20 0.54
HTR1A P08908 1/20 0.54
PDE6A P16499 1/20 0.54
PDE6G P18545 1/20 0.54
PDE4A P27815 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3835985 0.91 PDE5A (0.68) PDE5APDE3BPDE3APDE1APDE1B
SCHEMBL3841161 0.89 PDE5A (0.64) PDE5APDE3BPDE3APDE1APDE1B
SCHEMBL7163161 0.88 PDE5A (0.64) PDE5APDE3BPDE3APDE1APDE1B
SCHEMBL7168383 0.87 PDE5A (0.66) PDE5APDE3BPDE3APDE1APDE1B
SCHEMBL3840535 0.85 PDE5A (0.68) PDE5APDE3BPDE3APDE1APDE1B
SCHEMBL7167327 0.82 PDE5A (0.66) PDE5APDE3BPDE3APDE1APDE1B
SCHEMBL3840503 0.81 PDE5A (0.72) PDE5APDE3BPDE3APDE1APDE1B
Lodenafil SCHEMBL31202790 0.80 PDE5A (1.00) PDE5APDE3BPDE3APDE1APDE1B
SCHEMBL6485584 0.80 PDE5A (0.81) PDE5APDE3BPDE3APDE1APDE1B
Lodenafil SCHEMBL1058 0.80 PDE5A (1.00) PDE5APDE3BPDE3APDE1APDE1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6562830-B1 Compounds which prevent or induce the remission of existing precancerous or cancerous lesions or carcinomas would greatly reduce illness and death from cancer CELL PATHWAYS, INC. 2003-05-13 US disclosed
EP-0628032-B1 QUINAZOLINONE ANTIANGINAL AGENTS PFIZER LTD (GB) 1998-05-13 EP disclosed
WO-1993012095-A1 QUINAZOLINONE ANTIANGINAL AGENTS PFIZER LIMITED (GB) 1993-06-24 WO disclosed